Richard Gonzalez, AbbVie CEO (Chris Kleponis via AP Images)
June 17, 2022 12:42 PM EDT
Pharma
FDA+

Push­ing for top spot in Big Phar­ma, Ab­b­Vie lands a key ap­proval for its block­buster Skyrizi

John Carroll

Editor & Founder

Ab­b­Vie just scored an­oth­er win in its cam­paign to make Skyrizi one of the top block­busters in the port­fo­lio while push­ing the Big Phar­ma to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times